Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

PHARMACOLOGY OF TRIMETHYL [2-(2,6-DIMETHYLPHENOXY)PROPYL]-TRIMETHYLAMMONIUM CHLORIDE, MONOHYDRATE; COMPOUND 6890 OR βTM 10

R. A. Mclean, R. J. Geus, J. Pasternack, P. A. Mattis and G. E. Ullyot
Journal of Pharmacology and Experimental Therapeutics May 1960, 129 (1) 17-23;
R. A. Mclean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. J. Geus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Pasternack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. A. Mattis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. E. Ullyot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Compound 6890, [2-(2,6-dimethylphenoxy) propyl]-trimethylammonium chloride monohy-drate or βTM 10 has been shown able to lower blood pressure and reduce heart rate in laboratory animals.

These effects were seen in acute tests on anesthetized cats and dogs. They were also obtainable with long-term administration in unanesthetized animals.

Pressor reflexes such as those following carotid artery occlusion or afferent vagal faradization were inhibited by 6890.

A mode of action resembling that outlined for TM 10 by Exley (1957) was established for this analog. Its unique blocking effect seems to be selective for sympathetic nerve endings.

Acute and 30-day toxicity tests did not reveal any histopathology or blood dyscrasia.

Clinical trial of 6890 against hypertension and peripheral vascular disease in man should add to our understanding of the basic mechanisms responsible for these conditions.

Footnotes

    • Received October 10, 1959.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 129, Issue 1
1 May 1960
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
PHARMACOLOGY OF TRIMETHYL [2-(2,6-DIMETHYLPHENOXY)PROPYL]-TRIMETHYLAMMONIUM CHLORIDE, MONOHYDRATE; COMPOUND 6890 OR βTM 10
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

PHARMACOLOGY OF TRIMETHYL [2-(2,6-DIMETHYLPHENOXY)PROPYL]-TRIMETHYLAMMONIUM CHLORIDE, MONOHYDRATE; COMPOUND 6890 OR βTM 10

R. A. Mclean, R. J. Geus, J. Pasternack, P. A. Mattis and G. E. Ullyot
Journal of Pharmacology and Experimental Therapeutics May 1, 1960, 129 (1) 17-23;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

PHARMACOLOGY OF TRIMETHYL [2-(2,6-DIMETHYLPHENOXY)PROPYL]-TRIMETHYLAMMONIUM CHLORIDE, MONOHYDRATE; COMPOUND 6890 OR βTM 10

R. A. Mclean, R. J. Geus, J. Pasternack, P. A. Mattis and G. E. Ullyot
Journal of Pharmacology and Experimental Therapeutics May 1, 1960, 129 (1) 17-23;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Ethnic Differences in N-Glucuronidation of Nicotine and Cotinine
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics